HOUSTON INNOVATORS PODCAST EPISODE 134

Cleantech accelerator leader looks forward to new cohort and making an impact on Houston's energy transition

Kerri Smith of the Rice Alliance joins the Houston Innovators Podcast to discuss Rice's Clean Energy Accelerator. Photo courtesy of Rice

Kerri Smith knows accelerators. Through her over 18 years at Rice Alliance, she's been responsible for overseeing several and was on the founding leadership team of Houston's first energy tech startup accelerator, SURGE. After years of focusing you accelerating Rice University's student-focused program, Owl Spark, she's transitioned back into the energy tech space.

"I've worked with many types of founders. There's not one unique characteristic that everyone has," Smith says on the Houston Innovators Podcast. "Our goal is to help move them along and help them move the needle. At the end of the day, we want them to have a good experience and to meet their goals and objectives."

The Rice Alliance's Clean Energy Accelerator launched last summer with its inaugural cohort of 12 cleantech startups, which represented energy sectors from solar and wind innovations to hydrogen, geothermal, and more. Smith says the startups represented a wide range of stages and were from all over — only two companies were from Houston originally. The out-of-town companies were able to make critical partnerships in town and set up a presence and a home here.

"We were able to build a family-like culture among our group, and that was something that was wildly appreciative," Smith, who serves as executive director of the program, says.

Applications for Class 2 of CEA are open until May 31. While the program will offer the same access to mentorship and opportunities, the program will change slightly. CEA will focus on seed and series A-stage companies and will be a hybrid program. Throughout the 10 weeks, which begins in the fall instead of the summer this year, founders will visit Houston three times at the beginning, middle, and the end of the accelerator. Each startup will receive a grant to cover the expenses of the equity-free program.

CEA is just one part of a greater ecosystem of innovation under the umbrella of Rice University, which includes the Rice Alliance for Technology and Entrepreneurship, the Liu Idea Lab for Innovation and Entrepreneurship, The Ion Houston, Owl Spark, and more. All these entities also play into the greater Houston area's innovation ecosystem.

"Rice Alliance has a strong history of demonstrating collaboration with a number of organizations," Smith says. "I think one of the primary benefits that we have in these collaborative opportunities is to ensure that we are collectively building a capable and diverse pipeline of talent to solve for these problems and provide them with access to experiencing all of the benefits of our ecosystem."

With CEA specifically, some of these collaborations include working with Greentown Houston, which is just next door to the program's home at The Ion, and the Greater Houston Partnership's Houston Energy Transition Initiative.

"We're a cog in the wheel. We do really well with that. We play well with others – in ways that the founder has a good experience and can benefit," Smith says.

Smith shares more about what she's looking for in the second cohort of CEA on the podcast episode, as well as what she sees as Houston's role in the energy transition. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted